Skip to main content
Erschienen in: Journal of Endocrinological Investigation 2/2021

01.02.2021 | Original Article

Association of MICA gene polymorphisms with thionamide-induced agranulocytosis

verfasst von: P. Ma, P. Chen, J. Gao, H. Guo, S. Li, J. Yang, J. Lai, X. Yang, B. Zhang, Y. He

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Thionamide-induced agranulocytosis (TIA), namely antithyroid drug (ATD)-induced agranulocytosis, is one of the most feared adverse effect of ATDs. It is defined as a granulocyte count of less than 0.5 × 109/L after ATD administration. Several studies reported that TIA is associated with human leukocyte antigen (HLA) and nearby genes. Our previous study found that the susceptibility genes of TIA are similar in north China and European populations.

Methods

We evaluated the associations of 23 candidate single nucleotide polymorphisms (SNPs) in 37 patients with TIA and 254 patients with Graves’ disease (GD) as controls by iPLEX MassARRAY system.

Results

Five SNPs in the MHC class I polypeptide-related sequence A(MICA) genes [rs4349859 (p = 1.43E-7); rs145575084 (p = 5.79E-6); rs116135464 (p = 3.70E-5); rs148015908 (p = 3.79E-5) and rs189600525 (p = 2.15E-4)] were found to be significantly associated with TIA after Bonferroni correction. After combining with previous data of rs4349859 and HLA-B*27:05, the haplotype analysis showed that patients carrying P-A-C-A-T-T-A haplotype have a higher risk of TIA (p = 9.76E-7; OR = 14.85, 95% CI 3.63–60.77).

Conclusion

Our findings suggest that five high linked SNPs of MICA gene are significantly associated with susceptibility to TIA.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Ross DS et al (2016) 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26:1343–1421CrossRef Ross DS et al (2016) 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26:1343–1421CrossRef
3.
4.
Zurück zum Zitat Watanabe N et al (2012) Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves' disease. J Clin Endocrinol Metab 97:E49–E53CrossRef Watanabe N et al (2012) Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves' disease. J Clin Endocrinol Metab 97:E49–E53CrossRef
5.
Zurück zum Zitat Cheung CL et al (2016) HLA-B* 38: 02: 01 predicts carbimazole/methimazole-induced agranulocytosis. Clin Pharmacol Ther 99:555–561CrossRef Cheung CL et al (2016) HLA-B* 38: 02: 01 predicts carbimazole/methimazole-induced agranulocytosis. Clin Pharmacol Ther 99:555–561CrossRef
6.
Zurück zum Zitat Nakamura H, Miyauchi A, Miyawaki N, Imagawa J (2013) Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metabol 98:4776–4783CrossRef Nakamura H, Miyauchi A, Miyawaki N, Imagawa J (2013) Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metabol 98:4776–4783CrossRef
7.
Zurück zum Zitat Kobayashi S et al (2014) Characteristics of agranulocytosis as an adverse effect of antithyroid drugs in the second or later course of treatment. Thyroid 24:796–801CrossRef Kobayashi S et al (2014) Characteristics of agranulocytosis as an adverse effect of antithyroid drugs in the second or later course of treatment. Thyroid 24:796–801CrossRef
8.
Zurück zum Zitat Kim HK et al (2015) Characteristics of Korean patients with antithyroid drug-induced agranulocytosis: a multicenter study in Korea. Endocrinol Metabol 30:475–480CrossRef Kim HK et al (2015) Characteristics of Korean patients with antithyroid drug-induced agranulocytosis: a multicenter study in Korea. Endocrinol Metabol 30:475–480CrossRef
9.
Zurück zum Zitat Csernok E, Ernst M, Schmitt W, Bainton D, Gross W (1994) Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol 95:244–250CrossRef Csernok E, Ernst M, Schmitt W, Bainton D, Gross W (1994) Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol 95:244–250CrossRef
10.
Zurück zum Zitat Owen CA, Campbell MA, Boukedes SS, Campbell EJ (1995) Inducible binding of bioactive cathepsin G to the cell surface of neutrophils. A novel mechanism for mediating extracellular catalytic activity of cathepsin G. J Immunol 155:5803–5810PubMed Owen CA, Campbell MA, Boukedes SS, Campbell EJ (1995) Inducible binding of bioactive cathepsin G to the cell surface of neutrophils. A novel mechanism for mediating extracellular catalytic activity of cathepsin G. J Immunol 155:5803–5810PubMed
11.
Zurück zum Zitat Vita R, Mazzi V, Antonelli A, Benvenga S (2013) Antithyroid medications and psychosis. Expert Opin Drug Saf 12:865–872CrossRef Vita R, Mazzi V, Antonelli A, Benvenga S (2013) Antithyroid medications and psychosis. Expert Opin Drug Saf 12:865–872CrossRef
12.
Zurück zum Zitat Chen P-L et al (2015) Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study. Nat Commun 6:7633CrossRef Chen P-L et al (2015) Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study. Nat Commun 6:7633CrossRef
13.
Zurück zum Zitat Thao MP, Tuan PVA, Linh LGH et al (2018) Association of HLA-B∗38:02 with Antithyroid Drug-Induced Agranulocytosis in Kinh Vietnamese Patients. Int J Endocrinol. 2018:7965346CrossRef Thao MP, Tuan PVA, Linh LGH et al (2018) Association of HLA-B∗38:02 with Antithyroid Drug-Induced Agranulocytosis in Kinh Vietnamese Patients. Int J Endocrinol. 2018:7965346CrossRef
14.
Zurück zum Zitat He Y et al (2017) Association of HLA-B and HLA-DRB1 polymorphisms with antithyroid drug-induced agranulocytosis in a Han population from northern China. Sci Rep 7:11950CrossRef He Y et al (2017) Association of HLA-B and HLA-DRB1 polymorphisms with antithyroid drug-induced agranulocytosis in a Han population from northern China. Sci Rep 7:11950CrossRef
15.
Zurück zum Zitat Hallberg P et al (2016) Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population. Lancet Diabetes Endocrinol 4:507–516CrossRef Hallberg P et al (2016) Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population. Lancet Diabetes Endocrinol 4:507–516CrossRef
16.
Zurück zum Zitat Zou Y, Stastny P (2010) Role of MICA in the immune response to transplants. Tissue Antigens 76:171–176CrossRef Zou Y, Stastny P (2010) Role of MICA in the immune response to transplants. Tissue Antigens 76:171–176CrossRef
17.
Zurück zum Zitat Tian W et al (2006) MICA-STR, HLA-B haplotypic diversity and linkage disequilibrium in the Hunan Han population of southern China. Int J Immunogen 33:241–245CrossRef Tian W et al (2006) MICA-STR, HLA-B haplotypic diversity and linkage disequilibrium in the Hunan Han population of southern China. Int J Immunogen 33:241–245CrossRef
19.
Zurück zum Zitat Ostrovsky O et al (2003) NQO2 gene is associated with clozapine induced agranulocytosis. Hum Immunol 10:S140CrossRef Ostrovsky O et al (2003) NQO2 gene is associated with clozapine induced agranulocytosis. Hum Immunol 10:S140CrossRef
20.
Zurück zum Zitat Turbay D et al (1997) Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups. Blood 89:4167–4174CrossRef Turbay D et al (1997) Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups. Blood 89:4167–4174CrossRef
21.
Zurück zum Zitat Barrett JC, Fry B, Maller J, Daly MJ (2004) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263–265CrossRef Barrett JC, Fry B, Maller J, Daly MJ (2004) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263–265CrossRef
22.
Zurück zum Zitat Askar M et al (2017) MHC class I chain-related gene A (MICA) donor-recipient mismatches and MICA-129 polymorphism in unrelated donor hematopoietic cell transplantations has no impact on outcomes in acute lymphoblastic leukemia, acute myeloid leukemia, or myelodysplastic syndrome: a center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant 23:436–444CrossRef Askar M et al (2017) MHC class I chain-related gene A (MICA) donor-recipient mismatches and MICA-129 polymorphism in unrelated donor hematopoietic cell transplantations has no impact on outcomes in acute lymphoblastic leukemia, acute myeloid leukemia, or myelodysplastic syndrome: a center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant 23:436–444CrossRef
23.
Zurück zum Zitat Martinez-Borra J et al (2000) HLA-B27 alone rather than B27-related class I haplotypes contributes to ankylosing spondylitis susceptibility. Hum Immunol 61:131–139CrossRef Martinez-Borra J et al (2000) HLA-B27 alone rather than B27-related class I haplotypes contributes to ankylosing spondylitis susceptibility. Hum Immunol 61:131–139CrossRef
24.
Zurück zum Zitat Yang H et al (2015) Histone deacetylase inhibitor SAHA epigenetically regulates miR-17–92 cluster and MCM7 to upregulate MICA expression in hepatoma. Br J Cancer 112:112CrossRef Yang H et al (2015) Histone deacetylase inhibitor SAHA epigenetically regulates miR-17–92 cluster and MCM7 to upregulate MICA expression in hepatoma. Br J Cancer 112:112CrossRef
25.
Zurück zum Zitat Yang J et al (2018) Decreased miR-17-92 cluster expression level in serum and granulocytes preceding onset of antithyroid drug-induced agranulocytosis. Endocrine 59:218–225CrossRef Yang J et al (2018) Decreased miR-17-92 cluster expression level in serum and granulocytes preceding onset of antithyroid drug-induced agranulocytosis. Endocrine 59:218–225CrossRef
26.
Zurück zum Zitat Pan J et al (2017) Resveratrol promotes MICA/B expression and natural killer cell lysis of breast cancer cells by suppressing c-Myc/miR-17 pathway. Oncotarget 8:65743CrossRef Pan J et al (2017) Resveratrol promotes MICA/B expression and natural killer cell lysis of breast cancer cells by suppressing c-Myc/miR-17 pathway. Oncotarget 8:65743CrossRef
Metadaten
Titel
Association of MICA gene polymorphisms with thionamide-induced agranulocytosis
verfasst von
P. Ma
P. Chen
J. Gao
H. Guo
S. Li
J. Yang
J. Lai
X. Yang
B. Zhang
Y. He
Publikationsdatum
01.02.2021
Verlag
Springer International Publishing
Erschienen in
Journal of Endocrinological Investigation / Ausgabe 2/2021
Elektronische ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-020-01319-0

Weitere Artikel der Ausgabe 2/2021

Journal of Endocrinological Investigation 2/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Ist Fasten vor Koronarinterventionen wirklich nötig?

Wenn Eingriffe wie eine Koronarangiografie oder eine Koronarangioplastie anstehen, wird häufig empfohlen, in den Stunden zuvor nüchtern zu bleiben. Ein französisches Forscherteam hat diese Maßnahme hinterfragt.

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

04.06.2024 Typ-2-Diabetes Nachrichten

Wenn ältere Menschen mit Typ-2-Diabetes Schwierigkeiten beim Beschaffen und Zubereiten von Mahlzeiten haben, geht dies mit einem deutlich gesteigerten Risiko für schwere Hypoglykämien einher.

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

03.06.2024 Semaglutid Nachrichten

Der GLP-1-Agonist Semaglutid hat in der FLOW-Studie bewiesen, dass sich damit die Progression chronischer Nierenerkrankungen bei Patienten mit Typ-2-Diabetes bremsen lässt. Auch in kardiovaskulärer Hinsicht war die Therapie erfolgreich.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.